Novel Alzheimer's therapy shows low risk of severe side effects

OSU looking for those with early Alzheimer's to participate in study

COLUMBUS, Ohio (WCMH) -- Ohio State University is in a recruiting state, but it has nothing to do with football. OSU is looking for people who are in the early stages of Alzheimer's to take part in a nationwide drug trial for a synthetic version of Vitamin B1. The drug is Benfotiamine, and lead researcher, Dr. Douglas Scharre, said it is critical for brain processing. "People who are deficient in Vitamin B1 can have significant problems with the…

Drug to slow Alzheimer's well tolerated outside of clinical trial setting

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions.

Novel Alzheimer's therapy shows low risk of severe side effects

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease.

Side Effects Update: Lecanemab To Slow Alzheimer's

In 2023, the U.S. Food and Drug Administration an Alzheimer’s therapy shown in clinical trials to modestly slow disease progression but side effects, brain swelling and bleeding, occurred in some.Though clinical trials have taken twice as long and cost twice as much due to government regulations, they can't  cover everything and a successful doesn't mean broader demographics won't show different effects. Lawyers are gleeful at the opportunity to…